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1. Introduction
1.1. General overview of diabetic mellitus
Diabetes mellitus is a metabolic disorder that is characterized by hyperglycemia associat‐
ed  with  impairment  in  insulin  secretion  and/or  insulin  action  as  well  as  aberrations  in
intermediary metabolism of carbohydrates, proteins and lipids. Several reports indicate that
annual incidence rate of diabetes mellitus will increase in the future worldwide, especial‐
ly in the developing countries [1]. The effects of diabetes mellitus include long-term damage,
dysfunction  and failure  of  various  organs.  Diabetes  mellitus  may present  with  classical
characteristic  features  such as  blurring of  vision,  excessive thirst  (polydypsia),  excessive
feeding  (polyphagia)  excessive  urination  (polyuria),  and weight  loss.  In  its  most  severe
forms,  ketoacidosis  may  develop  leading  to  stupor,  coma  and,  in  absence  of  effective
treatment death ensues [2].
Often symptoms are not severe, or may be absent, and consequently hyperglycaemia sufficient
to cause pathological and functional changes may be present for a long time before the
diagnosis is made. On the other hand, other chronic features of diabetes mellitus include
progressive development of the specific complications of retinopathy with potential blindness.
Nephropathy that may lead to renal failure with risk of foot ulcers, amputation, including
reproductive dysfunction [3-6]. People with diabetes are at increased risk of developing
cardiovascular, peripheral vascular and cerebrovascular disease [7-8]. These include processes
which destroy the beta cells of the pancreas with consequent insulin deficiency and ultimately
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resulting in insulin resistance. The abnormalities of carbohydrate, fat and protein metabolism
have also been shown to result in deficient action of insulin on target tissues resulting from
insensitivity or lack of insulin [9-10].
Figure 1. The structure of the pancreas which houses islets of Langerhans
Insulin resistance was recently reported to be associated with obesity and type 2 diabetes[11].
Recent studies suggest that a complex interaction between inflammation, endoplasmic
reticulum stress, oxidative stress, mitochondrial dysfunction and autophagy dysregulation
play an important role in insulin resistance. The stress-activated c-Jun N-terminal kinase (JNK)
has been increasingly recognized as a central mediator of insulin resistance [11] and suppres‐
sion of the JNK pathway has been shown to improve insulin resistance and glucose tolerance.
Also, hyperhomocysteinemia (HHcy) was found to induce insulin resistance in adipose tissue
via activation of JNK pathway [12].
2. Classifications of diabetic mellitus
The terms type 1 and type 2 are used for classification based on aetiological factors. The terms
insulin-dependent and non-insulin-dependent are used for classifying pathophysiological
conditions of diabetes mellitus regardless of the aetiological factors. However, it has been
noticed that failure to administer insulin in an insulin-dependent condition can lead to ketosis
and with resultant life threatening condition. In the same vein patients whose conditions do
not require insulin treatment for prevention of ketosis or for survival are known to require
insulin for glycaemic control and such patients are considered to be in a non-insulin-dependent
state [13].
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2.1. Type 1 diabetes mellitus
Type 1 diabetes mellitus is caused by insulin deficiency due to destruction of pancreatic
β-cells  principally via an autoimmune reaction that can be triggered by different factors
[14].  It  can  also  develop  in  association  with  certain  hereditary  factors,  such  as  Human
Leukocyte Antigen (HLA) alleles. Typically, destruction of pancreatic β-cells progresses to
absolute deficiency in insulin.  This condition develops rapidly in young people and has
been  found to  occur  in  any  age  group [14].  Similarly,  autoantibodies  against  islet  anti‐
gens (islet-associated antibodies)  have been shown to increase in the early phase of  the
disease.  Hence,  pancreatic  β-cell  destruction  involves  autoimmune  mechanisms.  There‐
fore, type 1 diabetes mellitus is also known as ‘autoimmune’ type 1 diabetes mellitus [14,
15-16].
2.2. Type 2 diabetes mellitus
Type 2 diabetes mellitus is one of the most common diseases of the western world and is
associated  with  cardiovascular  disease  [17].  Type  2  diabetes  mellitus  (formerly  called
NIDDM, type II or adult-onset) is characterized by insulin resistance in peripheral tissue
and an insulin secretory defect of the beta cell. This is the most common form of diabetes
mellitus and is highly associated with a family history of diabetes, old age, obesity and lack
of exercise. It is more common in women, especially women with a history of gestational
diabetes. Type 2 diabetes mellitus is characterized by derangement of carbohydrate, protein
and  fat  metabolism  [18].  Insulin  resistance  and  hyperinsulinemia  eventually  lead  to
impaired glucose tolerance [19].
Defective beta cells become exhausted, further fuelling the cycle of glucose intolerance and
hyperglycaemia. The aetiology of type 2 diabetes mellitus is multifactorial with evidence of
genetic involvement [20-21]. Types of diabetes mellitus of various known aetiologies are
grouped together to form the classification called "other specific types." This group includes
persons with genetic defects of beta-cell function (this type of diabetes was formerly called
MODY or maturity-onset diabetes in youth) or with defects of insulin action; persons with
diseases of the exocrine pancreas, such as pancreatitis or cystic fibrosis; persons with dysfunc‐
tion associated with other endocrinopathies (e.g., acromegaly); and persons with pancreatic
dysfunction caused by drugs, chemicals or infections. Diabetic cardiomyopathy (DCM) has
also been extensively reported in type 2 diabetes mellitus [22-25]. DCM is recognized as
asymptomatic progressing structural and functional remodelling in the heart of diabetics, in
the absence of coronary atherosclerosis and hypertension. Diabetic cardiomyopathy is a fairly
common cause of heart failure in the native population with type-2 diabetes mellitus and
results in high morbidity and mortality [22]. Few of the classical symptoms of DCM include
marked left ventricular (LV) systolic dysfunction, dysfunction of coronary microcirculation,
in relation with glycaemic levels, insulin resistance, sympathetic overdrive, endothelial
dysfunction, abnormalities of the angiotensin-renin system, and remodelling/hypertrophy,
diastolic dysfunction and impairment of coronary flow reserve (CFR) may be associated in
DM [22-24].
Some Selected Medicinal Plants with Antidiabetic Potentials
http://dx.doi.org/10.5772/57230
97
3. Global impact of diabetic mellitus
Diabetes mellitus is a disease common to all parts of the world [26]. It is a common and
very prevalent disease affecting the citizens of both developed and developing countries.
It  has  been estimated that  25% of  the world population is  affected by this  disease [27].
Currently,  India  has  got  the  largest  number  of  diabetics  and is  being called as  diabetic
capital  of  the  world.  Diabetes  has  significant  health  consequences  for  individuals  and
communities. In fact, many countries face large increases in the number of people suffer‐
ing from diabetes. The World Health Organization estimated that about 30 million people
suffered from diabetes in 1985 and the number increased to more than 171 million in 2000.
Additionally, it  has been estimated that the number will  increase to over 366 million by
2030 and that large increases will occur in developing countries, especially in people aged
between 45 and 64 years [28].
A large disparity in total health spending for diabetes among the top 80 most populous
countries exists, varying from USD 1.3 million to USD 198.0 billion. The country with the
highest  total  expenditure,  the  United States  of  America,  will  spend 52.7% of  the  global
expenditure.  India,  the country with the largest  population of  people living with diabe‐
tes, will spend an estimated USD 2.8 billion or less than 1% of the world total. The total
diabetes spending in the 18 countries in IDF’s African Region will be only USD 1.2 billion,
0.3% of the global total [29]. The absolute level of health expenditure in developing countries
appears to be quite low. The lowest 20 spending countries in the top 80 most populated
countries  will  spend less  than USD 50  per  person per  year  for  managing  diabetes  and
diabetes-related  complications.  Expenditure  at  this  level  cannot  even  cover  the  annual
wholesale cost of a generic oral agent capable of preventing acute, life-threatening hypergly‐
caemia [29].  Considering the health services and therapeutic  treatments needed to man‐
age diabetes and diabetes-related complications, more health care resources are required to
provide adequate diabetes care in the poor countries.
4. Diabetic mellitus and oxidative stress
Diabetes mellitus is associated with an increased risk of cardiovascular diseases mediated
via  oxidative  stress.  ROS  can  directly  damage  lipids,  proteins  or  DNA  and  modulate
intracellular  signaling  pathways,  such  as  mitogen  activated  protein  kinases  and  redox
sensitive  transcription  factors  causing  changes  in  protein  expression  with  irreversible
oxidative  modifications  [30-31].  Hyperglycaemia-induced mitochondrial  dysfunction  and
endoplasmic reticulum stress has been shown to promote reactive oxygen species (ROS)
accumulation,  accelerates  cellular  damage  and  significantly  contributes  to  the  diabetic
complications  development  and  progression  [30,  32-33].  PA  et  al.  [34]  described  the
mechanism of cardiovascular dysfunction in diabetes mellitus (Figure 2).
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Figure 2. Mechanisms of cardiovascular dysfunction in diabetes: role of superoxide and peroxynitrite. Hyperglycaemia
induces increased superoxide anion (O2•−) production via activation of multiple pathways including xanthine and
NAD(P)H oxidases, cyclooxygenase, uncoupled nitric oxide synthase (NOS), glucose autoxidation, mitochondrial respi‐
ratory chain, polyol pathway, and formation of advanced glycation end products (AGE). Hyperglycaemia-induced in‐
creased superoxide generation may also favour an increased expression of nitric oxide synthases (NOS) through the
activation of NFκB, which may increase the generation of nitric oxide (NO). Superoxide anion may quench NO, thereby
reducing the efficacy of a potent endothelium-derived vasodilator system. Superoxide can also be converted to hydro‐
gen peroxide (H2O2) by superoxide dismutase (SOD) and interact with NO to form a reactive oxidant peroxynitrite
(ONOO−), which induces cell damage via lipid peroxidation, inactivation of enzymes and other proteins by oxidation
and nitration, and activation of matrix metalloproteinases (MMPs) among others. This figure was adapted from [34].
Hyperglycaemia-induced oxidative stress also mediates endothelial dysfunction which plays
a central role in the pathogenesis of micro- and macro-vascular diseases with resultant increase
in pro-inflammatory cytokines and induction of apoptosis and impairment of nitric oxide
release. Hyperglycaemia induces vascular damage probably through a single common
pathway - increased intracellular oxidative stress- linking four major mechanisms, namely the
polyol pathway, advanced glycation end-products (AGEs) formation, the protein kinase C
(PKC)-diacylglycerol (DAG) and the hexosamine pathways [35]. However, synthetic drugs
against diabetes mellitus have been reported with avalanche of side effects (Table 1) as reported
by Kavishankar et al. [36].
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Agent Mechanism Site of action Advantages Side effects
Sulphonylureas
Stimulating insulin
production
by inhibiting the K-
ATP
channel
Pancreatic beta cells Effective andinexpensive
Hypoglycaemia and
weight gain.
Metformin Decreases insulinresistance Liver
Weight loss
Does not cause
hypoglycaemia
Nausea and diarrhoea.
Hypoglycaemia occurs
when combined with
sulfonylurea or insulin
Thiazolidinediones
Reduce insulin
resistance by
activating PPAR-γ
GI tract Low risk
Increased liver enzymes,
weight
gain, oedema, mild
anaemia
α-glucosidase inhibitors
Reduces intestinal
glucose
absorption
Fat, muscle
Decreases
postprandial
plasma triglyceride
levels
Diarrhoea, abdominal
pain, flatulence;
Serum levels of
transaminases increases at
doses
Adapted from Kavishankar et al. [36].
Table 1. Synthetic drugs and their side effects
5. Drug-induced diabetic mellitus and their mechanisms of action
The most common drugs that are currently being used for the experimental induction of
diabetes are alloxan and streptozotocin (STZ). Streptozotocin (STZ) is a synthetic antineoplas‐
tic agent that is classified as an anti-tumour antibiotic and is chemically related to other
nitrosureas used in cancer chemotherapy [37]. Intra-venous injection of 60mg/kg dose of
streptozotocin in adult Wistar rats, makes pancreas swell and at last causes degeneration in
Langerhans islet beta cells and induces experimental diabetes mellitus in 2-4 days [37]. Both
alloxan and STZ have been extensively documented for the induction of diabetes via free
radical generation and depletion of antioxidant defense system [38-40]. STZ has been reported
to significantly decrease the activity of erythrocytes antioxidative enzymes catalase (CAT),
superoxide dismutase (SOD) and glutathione peroxidase (GPx) [38-39]. Several drugs, with
pharmacological properties including theophylline, aspirin, isoniazid and nalidixic acid can
cause transient hyperglycaemia in over dosage, but only streptozotocin, alloxan and the
rodenticide vacor are likely to cause permanent diabetes. Alloxan and the product of its
reduction, dialuric acid, establish a redox cycle with the formation of superoxide radicals that
undergo dismutation to produce hydrogen peroxide via Fenton reaction [41]. Similarly, the
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reactive oxygen species results in simultaneous massive increase in cytosolic calcium concen‐
tration causes rapid destruction of B cells. In the same vein, streptozotocin enters the B cell via
a glucose transporter (GLUT2) and causes alkylation of DNA. DNA damage induces activation
of poly ADP-ribosylation, a process that is more important for the diabetogenicity of strepto‐
zotocin than DNA damage itself. More so, Poly ADP-ribosylation leads to depletion of cellular
NAD+ and ATP [41]. Enhanced ATP dephosphorylation after streptozotocin treatment
supplies a substrate for xanthine oxidase resulting in the formation of superoxide radicals.
Also, streptozotocin liberates toxic amounts of nitric oxide that inhibits aconitase activity and
participates in DNA damage [41].
6. Some scientifically validated antidiabetic plants
Recently, Etuk et al. [42] reported that the following medicinal plants have been validated
scientifically as potent antidiabetic plants: Acacia arabica (Lam.) Muhl. ex Willd. (Family:
Mimosaceae), Aegle marmelos (L.) Correa ex Roxb. (Family: Rutaceae), Allium cepa L. (Family:
Liliaceae), Allium sativum L. (Family: Alliaceae), Aloe vera (L.) Burm.f. (Family: Aloaceae),
Anthemis mobilis Linn. (Family: Compositae), Areca catechu L. (Family: Arecaceae), Artemisia
pallens Wall. ex DC. (Family: Compositae), Annona squamosa L. (Family: Annonaceae),
Andrographis paniculata Nees (Family: Acanthaceae), Aerva lanata (L.) Juss. ex Schult. (Family:
Amaranthaceae), Asteracantha longifolia Nees (Family: Acanthaceae), Azadirachta indica A. Juss.
(Family: Meliaceae), Biophytum sensitivum (L.) DC. (Family: Oxalidaceae), Bombax ceiba L.
(Family: Bombacaceae), Beta vulgaris
L. (Family: Chenopodiaceae), Brassica juncea (L.) Czern. (Family: Brassicaceae), Barleria
lupulina Lindl. (Family: Acanthaceae), Boerhavia diffusa L. (Family: Nyctaginaceae), Brickellia
veronicaefolia A. Gray (Family: Asteraceae), Cassia auriculata L. (Family: Leguminosae),
Caesalpinia bonducella (L.) Roxb. (Family: Cesalpinaceae), Capparis decidua (Forsk.) Edgew.
(Family: Capparidaceae) Cajanus cajan (L.) Millsp. (Family: Fabaceae), Citrullus colocynthis (L.)
Schrad. (Family: Cucurbitaceae), Coccinia indica Wight & Arn. (Family: Cucurbitaceae), Casearia
esculenta Roxb. (Family: Flacourtiaceae), Catharanthus roseus (L) G. Don. (Family: Apocyna‐
ceae), Camellia sinensis Kuntze (Family: Theaceae), Coriandrum sativum L. (Family: Apiaceae).
7. Antidiabetic plants in clinical trials
The following antidiabetic plants are currently under clinical trials viz:
Allium cepa L., Clerodendron phlomoides Linn., Cinnamomum tamala (Buch.-Ham.) T. Nees & Eberm.,
Coccinia indica Wight & Arn., Enicostemma littorale Blume, Ficus bengalensis L., Momordica
charantia L., Pterocarpus marsupium Roxb., Cyamopsis tetragonolobus (L.) Taub., Cephalandra indica
Naud., Casearia esculenta Roxb., Cannabis indica (Lam.) E. Small & Cronq., and Syzygium cumini L.
when subjected to clinical trials, showed promising hypoglycaemic effects [43]. Other potent antidiabetic
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plants in this category include Cecropia obtusifolia, Marrubium vulgare, Asteracantha longifolia Nees
L., Panax quinquefolius L, Gymnema Sylvestre, Phyllanthus amarus, Opuntia streptacantha Lem.
They were found to produce beneficial effects on carbohydrate and lipid metabolisms when
administered as an adjunct on patients with type 2 diabetes [44]. These plants have been
reported to improve glucose tolerance in healthy human subjects and diabetic patients, caused
significant reduction in blood glucose, glycosylated haemoglobin and glycosylated plasma
proteins comparable to an oral hypoglycaemic drug [45].
8. General mechanism (s) of action of medicinal plants with antidiabetic
property
Different mechanisms of action of medicinal plants with anti-diabetic have been extensively
described. These include inhibition of renal glucose reabsorption [46], stimulation of insulin
secretion from beta cells of islets or/and inhibition of insulin degradative processes, reduction
in insulin resistance [47] regenerating and/or repairing pancreatic beta cells with increasing
the size and number of cells in the islets of Langerhans [45]. Stimulation of insulin secretion
[48] and stimulation of glycogenesis and hepaticglycolysis [49] with antidiabetic plants is well
established. Also, protective effect on the destruction of the beta cells and improvement in
digestion along with reduction in blood sugar urea has been documented [50]. Prevention of
pathological conversion of starch to glucose, and inhibition of β-galactocidase, α-glucocidase
and alpha-amylase with concomitant capacity to lower cortisol has also been reported [51-52].
Antioxidant activity of antidiabetic plant against oxidative stress which is involved in
pancreatic ß-cell dysfunction has been reported as one of the mechanisms of action of anti‐
diabetic plants [53]. Similarly, some plant families reported for antidiabetic activity are shown
below (Table 2).
9. Antioxidant activity of medicinal plants with antidiabetic activity
One of the major pathogenic mechanisms of diabetes mellitus include generation of oxidative
stress, increase generation of free radicals and an impaired antioxidant defence system with
concomitant imbalance of the oxidant/antioxidant status [54]. Inhibition of this cascade of
oxidative processes has been reported to prevent the onset and development of diabetic
complications [55]. Antidiabetic plants have been documented to scavenge free radicals,
quench electronically excited compounds, reduce hydroperoxide formation, and attenuate
production of reactive oxygen species (ROS) through modulation of several enzymes including
xanthine oxidase, cyclooxygenase, lipoxygenase, microsomal monooxygenase, NADH
oxidase and mitochondrial succinoxidase [56]. More so, plant phytonutrients such as poly‐
phenols are known to enhance the endogenous antioxidative system, improve oxidant
antioxidant balance, prevent oxidative damage, decrease lipid peroxidation, increase plasma
total antioxidant capacity and induce antioxidant enzymes including superoxide dismutase,
catalase and glutathione peroxidase [57].
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10. Plant phytochemicals associated with antidiabetic activity
Photochemicals or phytonutrients are chemical compounds that occur naturally in plants that
have protective or disease preventive properties [58]. Each type of fruit or vegetable may
contain hundreds of phytochemicals. They have been reported to show multiple beneficial
effects in combating diabetes and diabetes related complications [58]. The widest known
Botanical Family
Mangifera indica Anacardiaceae
Senna occidentalis Fabaceae
Euphorbia convuludiodes Euphobiaceae
Khaya senegalensis Meliaceae
Acacia nilotica Mimosaceae
Vernonia amygdalina Asreraceae
Fiscus thonnigii Moraceae
Angeissus leiocarpus Combretaceae
Gossypium hirsutum Malvaceae
Vitillarta paradoxa Sapotaceae
Anacardium occidentalis Anacardiaceae
Anana senegalensis Anonaceae
Psidium guajava Myrtaceae
Moringa oleifera Mringaceae
Azadirachata indica Meliaceae
Alluvium cepa Liliaceae
Ctrus medica Rutaceae
Parkta filicoidea Mimosaceae
Allium sativum Liliaceae
Balanites aegyptiaca Zygophyliaceae
Bauhinia reticulate Casalpiniaceae Casalpiniaceae
Adapted from Etuk et al., 2010
Table 2. Some plant families reported for antidiabetic activity
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groups of phytochemicals are the alkaloids, terpenes, and phenolics. Plant constituents such
as polysaccharides, peptides, alkaloids, glycopeptides, triterpenoids, amino acids, steroids,
xanthone, flavonoids, lipids, phenolics, coumarins, iridoids, alkyl disulphides, inorganic ions
and guanidines are reported to have antidiabetic activities [49, 59]. More interestingly, the
following phytochemicals are reported to have antidiabetic activity, aminoacids like hypo‐
glycin A and hypoglycin B, alkaloids like catharanthine, leurosine, lochnerine, arecoline and
vindoline, pinitol, epicatechin, S-methyl cysteine sulphoxide, S-allyl cysteine sulphoxide,
andrographolide, allicin (thio-2-propene-1- sulfinic acid S-allyl ester), shamimin, beta vul‐
garosides I–IV, glycoside of leucopelargonidin and leucodelphinidin, mangiferin, marsupsin,
pterosupin, pterostilbene, salacinol, swerchirin, trigonelline, berberine, harmane, norharmane,
pinoline, quercetin, chlorogenic acid, hesperidin, naringin, epigallocatechin gallate, charantin,
galactonmannan, lactucain C, kaempferol glucosides, caffeoyl glucoside, bakuchiol, swerchir‐
in, thysanolactone, bellidifolin and kolaviron have been documented for potential phytonu‐
trients [60].
11. Plant phytochemicals associated with insulinomimetic activity
They stimulate Beta cell rejuvenation, regeneration and stimulation increase insulin level,
Irneccerepatoser insulin secretion and reduction of insulin binding on the insulin [34]. Some
of the plant phytochemicals associated with insulinomimetic activity include the following:
Abies pindrow Pinaceae, Acacia arabica (Leguminosae), Agrimony eupatoria (Rosaceae), Aloe
barbadensis (Liliaceae), Annona squamosa (Annonaceae), Averrhoa bilimbi (Oxalidaceae),
Bixa orellana (Bixaceae), Boerhaavia diffusa (Nyctaginaceae), Camellia sinensis (Theaceae),
Capsicum frutescens (Solanaceae), Cinnamomum zeylanicum (Lauraceae), Clausena anisata
(Rutaceae), Eucalyptus globulus (Myrtaceae), Ficus religiosa (Moraceae), Hibiscus rosa
(Malvaceae), Helicteres isora (Sterculiaceae), Ipomoea batata (Convolvulaceae) Juniperus
communis (Pinaceae), Olea europia (Oleaceae), Swertia chirayata (Gentianaeae), Scoparia
dulcis (Scrophulariaceae),Tinospora crispa (Menispermaceae) Urtifca dioica (Urticaceae),
Vinca rosea (Apocynaceae), Zingiber officinale (Zingiberaceae).
12. Some selected medicinal plants with antidiabetic potentials in Nigeria
In Nigeria, two plants, Mangifera indica and Vernonia amygdalina have been ranked highest for
their antidiabetic property. Diabetes mellitus is known to affect 3% on average of adult
Nigerians [61] and the prevalence in northern Nigerian is put at 1.6% [62]. Some of the selected
medicinal plants with antidiabetic potentials in Nigeria are listed below.
Mangifera indica, Angeissus leiocarpus, Fiscus thonnigii, Khaya senegalensis,. Euphorbia convuludi‐
odes, Acacia nilotica, Vernonia amygdalina,Cassia goratensis,Cassia arereh, Calotropis procera, Senna
occidentalis, Alluvium cepa, Ipomoea batatas, Vitex gekowskii,Ctrus medica, Parkta filicoidea, Allium
sativum, Anacardium occidentalis, Azadirachata indica,Vitillarta paradoxa, Gossypium hirsutum,
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Lawsonia inermis, Moringa oleifera, Psidium guajava, Bauhinia reticulate, Balanites aegyptiaca,
Lannea kerstingii, Daucus carota, Zizyphus spina, Anana senegalensis, Eugenia caryophyllata, Blighia
sapida.
The leaves of Mangifera indica are used as an antidiabetic agent in Nigerian folk medicine. The
hypoglycemic activity of Mangifera indica has been reported in both rats and mice [63-64].
Aqueous extract of the leaves of Mangifera indica were found to possess hypoglycaemic activity
against glucose-induced hyperglycaemia but not with normoglycaemic or STZ-induced
diabetic rats and mice respectively [63-64]. The hypoglyceamic effect of this plant was thought
to be by reduction of intestinal absorption of glucose. Antihyperglycaemic activity of aqueous
stem bark extract of Mangifera indica was also reported by Ojewole [65]. The extract from the
stem bark of Mangifera indica administered intraperitoneally in streptozotocin induced
diabetics rats produced a significant reduction in blood glucose level in rats Ojewole [65].
In Nigeria, the leaves of Vernonia amygdalina Del. (VA) and Azadirachta indica A. Juss (AI) have
been used traditionally as a remedy against diabetes mellitus [66]. Atangwho et al. [66]
reported that significant antidiabetic effect of the combination therapy was achieved when VA
and AI were combined. The mechanism of action of the combination therapy was proposed
as attenuation of oxidative stress, insulin mimetic action and β-cell regeneration. The presence
of flavonoids such as luteolin, luteolin 7-O-β-glucuronoside, and luteolin 7-O-β-glucoside has
been shown to be responsible for the antioxidant activity of Vernonia amygdalina [67]. The
presence of these flavonoids could therefore contribute significantly to the antidiabetic
property of Vernonia amygdalina.
Etuk and Mohammed [68] reported that 200 mg/kg of V. amygdalina, C. procera, C. goratensis
and M. indica aqueous extracts produced a significant (p < 0.05) reduction in the blood glucose
levels of the rats in alloxan-induced diabetic mellitus. In the same vein, A. leicarpus, C. arereh
and G. hirsutum extracts produced a non-significant reduction (p > 0.05) in blood glucose levels
in rats after treatment. Similarly, aqueous extracts of M. Oleifera, S. occidentalis and K. senegal‐
ensis were found to produce a minimal effect (about 4% reduction) on the alloxan-induced
hyperglycemia in rats (Etuk and Mohammed, 2009). In summary, Etuk and Mohammed (2009)
reported that 200mg/kg body weight of Vernonia amygdalina (67%), Calotropis procera (59%),
Cassia gorotensis (53%) and Magnifera indica (35%) extracts produced a significant (p < 0.0.5%)
reduction in blood glucose levels in diabetic rats while Angeissus leiocarpus (30%), Cassia arereh
(19%), Gossypium hirsutum (17%), Khaya senegalensis (4%), Senna occidentalis (4%) and Moringa
oleifera (4%) produced a nonsignificant (p <0.05%) effect.
Previous study showed that aqueous leaves extract of Psidium guajava (PG) at 250 mg/kg
showed statistically significant hypoglycaemic activity on alloxan-induced diabetic rats [69].
A 4-week supplementation of PG (125 and 250 mg/kg) in streptozotocin (STZ)-induced diabetic
rats was shown to protect pancreatic tissues, including islet β-cells, against lipid peroxidation
and DNA strand breaks induced by STZ, thereby reducing the loss of insulin-positive β-cells
and insulin secretion [70]. More so, PG was found to markedly inhibited pancreatic nuclear
factor-kappa B protein expression induced by STZ and restored the activities of antioxidant
enzymes, including superoxide dismutase, catalase, and glutathione peroxidase [70].
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1 ml Allum cepa solution (0.4 g A. cepa/rat) has been shown to increase the fasting serum high-
density lipoprotein levels and caused reduction of hyperglycaemia in streptozotocin (STZ)
diabetic rats [71]. The hypoglycaemic and hypolipidaemic activities of A. cepa were associated
with antioxidant activity via decrease superoxide dismutase (SOD) activity while no increased
lipid hydroperoxide and lipoperoxide concentrations in diabetic rats treated with A. cepa [71].
In another experiment, onion juices exerted antioxidant and antihyperglycemic effects on
alloxan-induced diabetes and consequently ameliorated liver and renal damage associated
with alloxan toxicity [72].
Flavonoids from Ipomoea batatas leaf (FIBL) was reported to have anti-diabetic activity on
alloxan-induced diabetic mice [73]. FIBL treatment (50, 100, and 150 mg/ kg body weight) for
28 days resulted in a significant decrease in the concentration of fasting blood glucose (FBG),
total cholesterol (TC) and triglyceride (TG) in diabetes mellitus mice [73]. Also, FIBL signifi‐
cantly increased body weight (bw) and serum high-density lipoprotein cholesterol (HDL-c)
level [73]. Stress and inflammation-related p38 mitogen-activated protein kinase activity and
tumour necrosis factor-α production of diabetic rats were significantly depressed by Ipomoea
batatas administration [74]. Similarly, histological examination also revealed improvement of
pancreatic β-cells mass after treatments with Ipomoea batatas [74]. Blighia sapida has also been
reported to have several ethnomedicinal uses of which various preparations and extracts have
been made for the treatment of diseases such as dysentery, epilepsy, yellow fever and diabetes
[75]. Saidu et al. [76] recently reported that Anacardium occidentale leaves at 300mg/kg body
weight showed significant hypoglycaemic activity in alloxan-induced diabetic rats comparable
to the standard drug-metformin.
13. Conclusion
Diabetes mellitus is a metabolic disorder in the endocrine system. It is known to be a dreadful
disease that is found in all parts of the world with a serious threat to the health of mankind.
Diabetes mellitus affect most of the people of both developed and developing countries. There
are lots of synthetic drugs that have been used to control and to treat diabetic patients with
partial recovery from this dreaded disease. Alternative to these synthetic agents, plants
provide a potential source of hypoglycemic drugs and are widely used in several traditional
systems of medicine to prevent diabetes. Several medicinal plants have been investigated for
their beneficial use in different types of diabetes. Several phytonutrients have been identified
from medicinal plants and this presents an exciting opportunity for the development of new
types of therapeutics for diabetes mellitus. Most abundant phytonutrients present in medicinal
plants are the alkaloids, terpenes, and phenolics. Phytomedicine has been used since ancient
time in many parts of the world where access to modern medicine is limited. Despite consid‐
erable progress in the treatment of diabetes by oral hypoglycemic agents, search for newer
drugs continues because the existing synthetic drugs have several limitations as shown in table
1. The treatment of diabetes with synthetic drugs in the developing countries is expensive due
to poverty and lack of access to Medicare. Hence, phytotherapy has significant role to play in
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the developing countries compared to synthetic drugs because it is safe, less expensive and
available as a gift of nature.
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